PharmaEngine

PharmaEngine Change in Working Capital

The Change in Working Capital of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 1.61 B TWD. In the previous year, Change in Working Capital was -1.65 B TWD — a change of -197.33% (higher).

Change in Working Capital

1.61 BTWD

YoY

-197.33%

Last updated:

Change in Working Capital of PharmaEngine is 2025 1.61 B TWD. Change in Working Capital of PharmaEngine was 2024 -1.65 B TWD. It decreases by -197.33% higher compared to the previous year.

The PharmaEngine Change in Working Capital history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Change in Working Capital
Date
Change in Working Capital
Jan 1, 2018
712.76 M TWD
Jan 1, 2019
-14.06 M TWD
Jan 1, 2020
-620.68 M TWD
Jan 1, 2021
576.02 M TWD
Jan 1, 2022
-27.51 M TWD
Jan 1, 2023
8.76 M TWD
Jan 1, 2024
-1.65 B TWD
Jan 1, 2025
1.61 B TWD
The PharmaEngine Change in Working Capital history
YEARChange in Working CapitalYoY
1.61 BTWD-197.33%
-1.65 BTWD-18,927.60%
8.76 MTWD-131.85%
-27.51 MTWD-104.78%
576.02 MTWD-192.80%
-620.68 MTWD+4,313.88%
-14.06 MTWD-101.97%
712.76 MTWD-193.00%
-766.39 MTWD-3,049.47%
25.98 MTWD+20.55%
21.55 MTWD-457.39%
-6.03 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

Change in Working Capital of PharmaEngine is 1.61 B TWD in 2025.

Change in Working Capital of PharmaEngine changed from -1.65 B TWD to 1.61 B TWD, representing a -197.33% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Change in Working Capital PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

Change in working capital reflects the period-over-period change in current assets minus current liabilities. It impacts operating cash flow significantly.

Change in Working Capital's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Change in Working Capital's PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — PharmaEngine

All Key Metrics — PharmaEngine